'Merck KGaA: Phase III Trials of Xevinapant in Locally Advanced Head & Neck Cancer Discontinued'
'Merck KGaA: Phase III Trials of Xevinapant in Locally Advanced Head & Neck Cancer Discontinued'
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.| Merck KGaA / Key word(s): Study results Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued 24-Jun-2024 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. |
| 默沙东股份有限公司/关键词：研究结果 默沙东：关于xevinapant用于局部晚期头颈癌的III期临床试验已被停止 2024年6月24日/19:00（欧洲中央时区/欧洲中央夏令时） 根据欧盟第596/2014号法规的第17条MAR披露内幕信息，EQS新闻通讯社（EQS Group AG）转发了此信息。 发行人对此公告的内容单独负责。 |
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
根据欧盟第596/2014号法规第17条披露内幕信息
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
默沙东：关于xevinapant用于局部晚期头颈癌的III期临床试验已被停止
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in patients who underwent resection of locally advanced head and neck cancer).
默沙东于2024年6月24日宣布，其正在进行一项III期临床试验（TrilynX），将xevinapant联合铂金化疗（CRT）与安慰剂联合CRT用于未切除的局部晚期头颈癌患者的治疗进行探究。公司决定停止该研究，该决定是根据研究的独立数据监测委员会进行的预定中期分析结果，该分析发现该试验不太可能达到其延长事件无进展生存期的主要目标。鉴于数据的总体情况，公司决定也停止xevinapant联合放疗与安慰剂联合放疗的III期临床试验（X-Ray Vision），该试验是针对已行局部晚期头颈癌切除的患者而进行的。
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.
xevinapant目前正在接受临床研究，尚未在全球任何地方获得批准用于任何适应症。
Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: esther.doeringer@merckgroup.com
Internet:
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Esther Döringer
默沙东股份有限公司。
法兰克福街250号
64293达姆施塔特
德国
电话：+49 151 1454 7809
电子邮件：esther.doeringer@merckgroup.com
互联网:
ISIN：DE0006599905
WKN：659990
指数：DAX
